

Applicant : Silviu Itescu
U.S. Serial No.: 10/693,480
Filed : October 23, 2003
Page 7 of Communication in Response to September 16, 2010 Office
Communication and Supplemental Information Disclosure Statement

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicant directs the Examiner's attention to the items listed below which are also listed on the Substitute PTO-1449 form attached hereto as **Exhibit B**. Documents 1-4 are U.S. Patents, and copies of these documents are not attached hereto as permitted by 37 C.F.R. §1.98(a)(2)(ii). Copies of items 5-25 are enclosed herewith as **Exhibits 1-21**, respectively.

1. U.S. Patent No. 7,220,407 issued to Mehta et al. on May 22, 2007;
2. U.S. Patent No. 7,473,425 issued to Fukuda et al. on January 6, 2009;
3. U.S. Patent No. 7,507,705 issued to Buschmann et al. on March 24, 2010;
4. U.S. Patent No. 5,451,399 issued to Gimbrone et al. on September 19, 1995;
5. March 23, 2010 Office Action issued in connection with U.S. Serial No. 11/894,555; (**Exhibit 1**)
6. PCT International Publication No. WO 99/17798-A1, published April 15, 1999; (**Exhibit 2**)
7. Hill et al. (2005) "Outcomes and Risks of Granulocyte Colony-Stimulating Factor in Patients with Coronary Artery Disease" Am coll Cardiol 46:1643-8; (**Exhibit 3**)

Applicant : Silviu Itescu

U.S. Serial No.: 10/693,480

Filed : October 23, 2003

Page 8 of Communication in Response to September 16, 2010 Office
Communication and Supplemental Information Disclosure Statement

8. Wang et al. (2005) "Effect of Mobilization of Bone Marrow Stem Cells by Granulocyte Colony Stimulating Factor on Clinical Symptoms, Left Ventricular Perfusion and Function in Patients with Severe Chronic Ischemic Heart Disease" Int J Cardiol 100:477-483; **(Exhibit 4)**
9. Werneck-de-Castro et al. (2006) "G-CSF Does Not Improve Systolic Function in a Rat Model of Acute Myocardial infarction" Basic Res Cardiol 101:494-501; **(Exhibit 5)**
10. Louzada et al. (2010) "Granulocyte-Colony Stimulating Factor Treatment of Chronic Myocardial Infarction" Cardiovasc Drugs Ther February 2, 2010; **(Exhibit 6)**
11. Srinivas et al. (2009) "Cytokines and Myocardial Regeneration" Cardiol Rev 17:1-9; **(Exhibit 7)**
12. Tomikawa et al. (1993) "Warm Renal Ischemia and Reperfusion Injury in Rats Treated with Cyclophosphamide and/or Granulocyte Colony-Stimulating Factor" Transplant Proc 25(6): 3230-3; **(Exhibit 8)**
13. Leong et al. (2000) "Neutrophil-independent Protective Effect of r-metHuG-CSF in Ischaemia-reperfusion Injury in Rat Skeletal Muscle" Int J Exp Path 81:41-49; **(Exhibit 9)**
14. Sullivan et al. (1993) "Effects of Perioperative Granulocyte Colony-stimulating Factor on Horses

Applicant : Silviu Itescu
U.S. Serial No.: 10/693,480
Filed : October 23, 2003
Page 9 of Communication in Response to September 16, 2010 Office
Communication and Supplemental Information Disclosure Statement

with Ascending Colonic Ischemia" Vet Surg
22(5):343-350; **(Exhibit 10)**

15. Squadrito et al. (1997) "The effects of Recombinant Human Granulocyte-colony Stimulating Factor on Vascular Dysfunction and Splanchnic Ischaemia-reperfusion Injury" Brit J Pharmacol 120:333-9; **(Exhibit 11)**
16. Phillips, A.J (2001) The Challenge of Gene Therapy and DNA Delivery" J Pharm Pharmacol 53:1169-74; **(Exhibit 12)**
17. April 28, 2010 Office Action issued in connection with Mexican Patent Application No. Pa/a/2002/012067; **(Exhibit 13)**
18. June 23, 2010 Office Action issued in connection with U.S. Serial No. 11/894,581; **(Exhibit 14)** and
19. Wheeler et al. (1988) "Cultured Human Endothelial Cells Stimulated with Cytokines or Endotoxin Produce an Inhibitor of Leukocyte Adhesion" J Clin Invest 82: 1211-1218; **(Exhibit 15)**
20. Gimbrone et al. (1989) "Endothelial Interleukin-8: a Novel Inhibitor of Leukocyte-endothelial Interactions" Science 246:1601-03; **(Exhibit 16)**
21. Hebert et al. (1990) Endothelial and Leukocyte Forms of IL-8" J Immunol 145:3033-40; **(Exhibit 17)**
22. De Simoni et al. (2008) "Silencing of peroxiredoxin

Applicant : Silviu Itescu
U.S. Serial No.: 10/693,480
Filed : October 23, 2003
Page 10 of Communication in Response to September 16, 2010 Office
Communication and Supplemental Information Disclosure Statement

3 and peroxiredoxin 5 reveals the role of
mitochondrial peroxiredoxins in the protection of
human neuroblastoma SH-SY5Y cells toward MPP+ "
Neuroscience Letters 433:219-224; **(Exhibit 18)**

23. Chang et al. (2002) "Regulation of peroxiredoxin I
activity by Cdc2-mediated phosphorylation" J Biol
Chem. 277:25370-6; **(Exhibit 19)**

24. August 3, 2010 Official Action issued in connection
with Japanese Patent Application No. 2003-587162;
(Exhibit 20)

25. May 26, 2010 Official Action issued in connection
with European Patent Application No. EP01942041.3;
(Exhibit 21)

This Supplemental Information Disclosure Statement is being
submitted under 37 C.F.R. §1.97(c)(2). Accordingly, applicant
authorizes the U.S. Patent Office to charge the amount of a ONE
HUNDRED AND EIGHTY DOLLARS (\$180.00) to Deposit Account No. 03-3125
for filing this Supplemental Information Disclosure Statement.

The Examiner is respectfully requested to make the listed
items of record in the present application by initialing and
returning a copy of the enclosed Substitute Form PTO 1449.

Applicant : Silviu Itescu

U.S. Serial No.: 10/693,480


Filed : October 23, 2003

Page 11 of Communication in Response to September 16, 2010 Office
Communication and Supplemental Information Disclosure Statement


If a telephone interview would be of assistance in advancing prosecution of the subject application, applicant's undersigned attorneys invite the Examiner to telephone him at the number provided below.

No fee, other than the enclosed \$180.00 Information Disclosure Statement fee, is deemed necessary in connection with the filing of this Communication and Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicant
Cooper & Dunham LLP
30 Rockefeller Plaza
20th Floor
New York, New York 10112
(212) 278-0400

Certificate of Transmission	
I hereby certify that this correspondence is being transmitted via the Electronic Filing System (EFS) to the U.S. Patent and Trademark Office on <u>October 18, 2010</u> .	
	<u>10/18/10</u>
John P. White	Date
Reg. No. 28,678	